research The protective role of the immunomodulator AS101 against chemotherapy-induced alopecia studies on human and animal models
AS101 reduces hair loss from chemotherapy.
Search
for
Sort by
Research
480-510 / 1000+ results
research Selective Expansion of Tregs Using the IL-2 Cytokine Antibody Complex Does Not Reverse Established Alopecia Areata in C3H/HeJ Mice
Increasing Treg cells in the skin does not cure hair loss from alopecia areata in mice.
research Immunization by Application of DNA Vaccine onto a Skin Area Wherein the Hair Follicles Have Been Induced into Anagen-onset Stage
Applying a DNA vaccine to skin with active hair growth boosts immune response and protection against anthrax in mice.
research Editors' Picks
New findings suggest targeting IL-23 could treat psoriasis, skin cells can adapt to new roles, direct conversion of skin cells to blood cells may aid cell therapy, removing certain tumor cells could boost cancer immunotherapy, and melanoma may have many tumorigenic cells, not just cancer stem cells.
research 15460 Perifollicular pink halo: A potential dermoscopic marker of inflammation in central centrifugal cicatricial alopecia
Certain immune markers may predict chemotherapy response in mesothelioma, and nivolumab is a tolerable and effective treatment for advanced non-small cell lung cancer.
research The Future of Systemic Lupus Erythematosus Treatment: The Promise of Selective Immunotherapies, Anifrolumab and Belimumab, Compared to Blanket Immunosuppressives
Selective immunotherapies like anifrolumab and belimumab are more effective for treating systemic lupus erythematosus than traditional drugs.
research Particle-based transcutaneous administration of HIV-1 p24 protein to human skin explants and targeting of epidermal antigen presenting cells
This method is effective for needle-free HIV-1 vaccination by activating immune responses in the skin.
research Large-Scale Epitope Identification Screen and Its Potential Application to the Study of Alopecia Areata
The conclusion is that a new method could improve the identification of autoimmune targets in alopecia areata, despite some limitations.
research Case Report: Dupilumab induced sustained complete remission in a child with severe alopecia areata and markedly elevated IgE
Dupilumab effectively treated severe alopecia areata in a child.
research 1114 Study of long-term (15-day) imiquimod treatment and drug intervention in localized psoriasiform dermatitis model
Long-term Imiquimod treatment causes initial skin inflammation that lessens over time, and topical corticosteroids reduce this inflammation and cytokines in a mouse model of psoriasis.
research A humanized IL-2 fusion protein enhances T regulatory cells in vivo and restrains disease in a murine model of Alopecia Areata 4760
A humanized IL-2 fusion protein boosts T regulatory cells and helps control hair loss in Alopecia Areata.
research 1389 Local injection with anti-herpes simplex virus antibodies protects against development of herpes simplex virus–induced sweating disturbance
Injecting anti-herpes antibodies locally can prevent skin lesions and sweating problems caused by herpes simplex virus in mice.
research Chronic delayed-type hypersensitivity reaction as a means to treat alopecia areata
SADBE treatment led to complete hair regrowth in mice with alopecia areata by altering immune cell movement.
research Microneedle Transdermal Drug Delivery Systems for Allergen-Specific Immunotherapy, Skin Disease Treatment, and Vaccine Development
Microneedles are a promising method for drug delivery, offering efficient and convenient alternatives with fewer side effects.
research Seventeen Cases of Alopecia Areata: Combination of SADBE Topical Immunotherapy with Other Therapies
Combining SADBE with other treatments can help hair regrowth in alopecia areata patients.
research Supplementary Material for: Plasma proteome–driven identification of druggable immune regulators of alopecia areata, validated by transcriptome and single-cell mapping
CD28 is a promising target for treating alopecia areata with belatacept.
research Supplementary Material for: Plasma proteome–driven identification of druggable immune regulators of alopecia areata, validated by transcriptome and single-cell mapping
CD28 is a promising target for treating alopecia areata with belatacept.
research Dermatologic Changes Associated With Interleukin 2 Administration
IL-2 treatment causes skin eruptions and other reversible side effects, and may play a role in psoriasis.
research Stimulation of Hair Growth by Topical Application of FK506, a Potent Immunosuppressive Agent
research Severe pustular lesions induced by topical immunotherapy with squaric acid dibutylester for alopecia totalis
Squaric acid dibutylester can cause severe skin reactions in people with allergies.
research Comparative efficacy and safety of systemic steroids, oral JAK inhibitors and Contact Immunotherapy in the Treatment of severe alopecia areata: a systematic review and network meta-analysis
Oral ritlecitinib and baricitinib are promising treatments for severe alopecia areata due to their balance of effectiveness and safety.
research Immune signatures of psoriasis: Comparison of genetic expression profiles in psoriasis patients after therapy with biologic agents
Treatment with biologic agents can significantly improve psoriasis symptoms, and blood biomarkers could potentially predict individual patient's response to treatment.
research Topische Immuntherapie mit Diphenylcyclopropenon bei verschiedenen Typen der Alpecia areata: Assoziation zu klinischen Parametern und einem funktionellen Genpolymorphismus des Interleukin-6-Promotors
Topical immunotherapy with DPCP is most effective for certain alopecia areata types, with success linked to age and disease duration, and influenced by a gene polymorphism.
research Type-2 immunity associated with type-1 related skin inflammatory diseases: friend or foe?
Type-2 immunity may influence skin diseases and could be targeted for treatment.
research BH17 Bridging the gap: identifying dual-targeting therapies for patients with alopecia areata and coexisting immune-mediated inflammatory diseases
Dual-targeting therapies like Janus kinase inhibitors may treat both alopecia areata and other immune diseases.
research Risk of Autoimmune Skin Diseases Associated With Immune Checkpoint Inhibitors: A Pharmacovigilance Analysis Using the FAERS Database
Immune checkpoint inhibitors can increase the risk of autoimmune skin diseases, especially bullous pemphigoid.
research Hair Regrowth Outcomes of Contact Immunotherapy for Patients With Alopecia Areata
Contact immunotherapy can improve hair regrowth in alopecia areata patients.
research Plasma proteome–driven identification of druggable immune regulators of alopecia areata, validated by transcriptome and single-cell mapping
Belatacept may be a promising treatment for alopecia areata.
research Biologics in the management of childhood atopic dermatitis
Biologics, especially Dupilumab, are effective and safe for treating severe childhood eczema.